Soligenix, Inc. (SNGX)
Largest Insider Buys in Sector
SNGX Stock Price History Chart
SNGX Stock Performance
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Insider Activity of Soligenix, Inc.
Over the last 12 months, insiders at Soligenix, Inc. have bought $0 and sold $0 worth of Soligenix, Inc. stock.
On average, over the past 5 years, insiders at Soligenix, Inc. have bought $21,758 and sold $2,701 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $8,866 was made by SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT) on 2022‑05‑18.
List of Insider Buy and Sell Transactions, Soligenix, Inc.
| 2022-05-18 | SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 20,000 0.0466% | $0.44 | $8,866 | +23.81% | ||
| 2022-05-18 | Straube Richard | SENIOR VICE PRESIDENT AND CMO | 8,000 0.021% | $0.50 | $4,000 | +23.81% | ||
| 2021-12-17 | SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 7,000 <0.0001% | $0.74 | $5,179 | -13.05% | ||
| 2021-12-15 | Guarino Jonathan L. | Senior Vice President and CFO | 1,000 <0.0001% | $0.70 | $700 | -10.86% | ||
| 2021-12-14 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 10,000 0.0001% | $0.73 | $7,269 | -7.05% | ||
| 2021-12-14 | Guarino Jonathan L. | Senior Vice President and CFO | 10,000 0.0001% | $0.71 | $7,119 | -7.05% | ||
| 2021-05-14 | Sale | ZELDIS JEROME B | director | 3,000 <0.0001% | $0.90 | $2,701 | +1.43% | |
| 2021-05-14 | ZELDIS JEROME B | director | 3,000 <0.0001% | $0.89 | $2,664 | +1.43% | ||
| 2019-11-19 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 10,770 0.0544% | $0.93 | $10,016 | +92.63% | ||
| 2019-11-19 | ZELDIS JEROME B | director | 2,000 0.0101% | $0.93 | $1,850 | +92.63% | ||
| 2019-09-23 | Parks Diane L. | director | 14,940 0.0003% | $0.93 | $13,870 | +95.33% | ||
| 2019-09-19 | ZELDIS JEROME B | director | 4,000 <0.0001% | $0.94 | $3,740 | +93.21% | ||
| 2019-04-22 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 5,000 0.0001% | $0.72 | $3,577 | +47.89% | ||
| 2019-04-22 | ZELDIS JEROME B | director | 10,000 0.0002% | $0.73 | $7,274 | +47.89% | ||
| 2018-10-18 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 8,700 0.0002% | $1.17 | $10,177 | -22.88% | ||
| 2018-10-17 | Pearson Mark E. | director | 170,000 0.0046% | $1.16 | $197,200 | -13.90% | ||
| 2018-08-22 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 3,530 <0.0001% | $1.42 | $5,012 | -30.71% | ||
| 2017-11-29 | Sale | Essetifin SPA | 16,416 0.0012% | $2.12 | $34,802 | -19.31% | ||
| 2017-11-29 | Essetifin SPA | 293,510 0.0223% | $2.12 | $622,241 | -19.31% | |||
| 2017-05-08 | Sale | KIRK RANDAL J | 10 percent owner | 11,576 0.0009% | $2.54 | $29,403 | -16.86% |
Insider Historical Profitability
| CAVAZZA PAOLO | 10 percent owner | 54227816 515.2581% | $2.73 | 3 | 0 | |
| CAVAZZA CLAUDIO | 10 percent owner | 54227816 515.2581% | $2.73 | 3 | 0 | |
| BAM Management LLC | 10 percent owner | 21766092 206.8155% | $2.73 | 1 | 1 | |
| Biotex Pharma Investments, LLC | 10 percent owner | 19000000 180.5329% | $2.73 | 0 | 2 | |
| Pearson Mark E. | director | 2500000 23.7543% | $2.73 | 1 | 0 | |
| KANZER STEVE H | director | 1282203 12.1831% | $2.73 | 1 | 0 | |
| LAPOINTE ANTHONY GREGG | director | 975610 9.27% | $2.73 | 1 | 0 | |
| Essetifin SPA | 293510 2.7889% | $2.73 | 4 | 1 | ||
| MYRIANTHOPOULOS EVAN | Chief Financial Officer | 224780 2.1358% | $2.73 | 2 | 0 | |
| SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 90095 0.8561% | $2.73 | 15 | 0 | +92.63% |
| Clavijo James | Controller/Treasurer | 88191 0.838% | $2.73 | 2 | 0 | |
| KIRK RANDAL J | 10 percent owner | 85397 0.8114% | $2.73 | 0 | 3 | |
| ZELDIS JEROME B | director | 25917 0.2463% | $2.73 | 6 | 1 | +47.03% |
| Brownlie Keith L | director | 19047 0.181% | $2.73 | 1 | 0 | |
| Parks Diane L. | director | 14940 0.142% | $2.73 | 1 | 0 | |
| Warusz Joseph Michael | VP of Finance/Acting CFO | 12955 0.1231% | $2.73 | 1 | 0 | |
| Guarino Jonathan L. | Senior Vice President and CFO | 11000 0.1045% | $2.73 | 2 | 0 | |
| Straube Richard | SENIOR VICE PRESIDENT AND CMO | 8000 0.076% | $2.73 | 1 | 0 | |
| RUBIN ROBERT J. | director | 4385 0.0417% | $2.73 | 2 | 0 | |
| Brughera Marco Maria | director | 2750 0.0261% | $2.73 | 1 | 0 |
Institutional Investor Ownership
No records found… | |||||||